Polynovo Ltd (ASX: PNV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Polynovo Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.31 billion
P/E Ratio 260.00
Dividend Yield 0.00%
Shares Outstanding 690.84 million
Earnings per share 0.008
Dividend per share N/A
Year To Date Return -4.41%
Earnings Yield 0.38%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Polynovo Ltd (ASX: PNV)
    Latest News

    Two lab workers fist pump each other.
    Healthcare Shares

    2 buy-rated ASX 200 healthcare shares to bring your portfolio to life in 2025

    Bell Potter is expecting healthy returns from these stocks this year.

    Read more »

    Share Market News

    Here are the top 10 ASX 200 shares today

    It was a day of relief and optimism for the S&P/ASX 200 Index (ASX: XJO)  and ASX investors this Tuesday.…

    Read more »

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Avita Medical, GenusPlus, Mesoblast, and Polynovo shares are storming higher

    These shares are having a better day than most today. But why?

    Read more »

    Man drawing an upward line on a bar graph symbolising a rising share price.
    Share Gainers

    Why EOS, News Corp, Polynovo, and Pro Medicus shares are roaring higher today

    These shares are starting the week positively. But why?

    Read more »

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    The best ASX 200 healthcare stocks to buy in 2025

    These shares could give your portfolio a healthy boost next year according to Bell Potter.

    Read more »

    a woman holds a facebook like thumbs up sign high above her head. She has a very happy smile on her face.
    Broker Notes

    Bell Potter names more of the best ASX 200 shares to buy in 2025

    Let's see why these shares have been given a big thumbs up by the broker ahead of the new year.

    Read more »

    The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
    Share Market News

    Here are the top 10 ASX 200 shares today

    ASX investors pushed the markets higher once more today...

    Read more »

    A young woman smiles as she rides a zip line high above the trees.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    ASX investors kicked off the trading week in style today.

    Read more »

    Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
    Broker Notes

    Healthcare, technology, and mining: 3 ASX stocks to buy now

    Add some diversity to your portfolio with these buy-rated shares from different sides of the market.

    Read more »

    Modern accountant woman in a light business suit in modern green office with documents and laptop.
    Share Market News

    7 ASX 200 directors sell huge chunks of company shares

    These sales took place over the past fortnight.

    Read more »

    A neon sign says 'Top Ten'.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was another day, and another record high for the ASX 200 this Tuesday.

    Read more »

    a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
    Broker Notes

    Morgans names more of the best ASX 200 stocks to buy in September

    These stocks are highly rated by analysts at Morgans in September. But why?

    Read more »

    Frequently Asked Questions

    The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was listed on the ASX  on 26 November 1998 and is headquartered in Melbourne.

    No, the company does not historically pay dividends.

    PNV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Polynovo Ltd

    PolyNovo Ltd (ASX: PNV) develops and commercialises innovative medical devices using its patented NovoSorb technology.

    NovoSorb is a family of biocompatible polymers that are used in the treatment of burns and surgical wounds. They biodegrade into by-products that can be absorbed and excreted by the body. For example, its NovoSorb BTM (Biodegradable Temporising Matrix) can be used to temporarily close a wound and aid the body in generating new tissue.

    PolyNovo’s products are sold across Australia and New Zealand, the United States, the United Kingdom, and Europe.

    PNV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    06 Feb 2025 $1.95 $0.00 0.00% 1,069,658 $1.97 $1.98 $1.93
    05 Feb 2025 $1.95 $-0.02 -1.02% 1,277,932 $2.00 $2.00 $1.93
    04 Feb 2025 $1.97 $0.03 1.55% 1,682,489 $1.99 $2.05 $1.97
    03 Feb 2025 $1.94 $-0.15 -7.18% 2,425,853 $2.05 $2.05 $1.93
    31 Jan 2025 $2.09 $-0.04 -1.88% 1,439,029 $2.12 $2.12 $2.07
    30 Jan 2025 $2.13 $-0.07 -3.18% 1,318,262 $2.19 $2.20 $2.13
    29 Jan 2025 $2.20 $0.01 0.46% 719,060 $2.20 $2.24 $2.18
    28 Jan 2025 $2.19 $-0.06 -2.67% 1,335,401 $2.24 $2.24 $2.17
    24 Jan 2025 $2.25 $-0.04 -1.75% 739,541 $2.30 $2.31 $2.24
    23 Jan 2025 $2.29 $0.00 0.00% 8,903,529 $2.30 $2.36 $2.29
    22 Jan 2025 $2.29 $0.03 1.33% 2,358,153 $2.28 $2.32 $2.26
    21 Jan 2025 $2.26 $0.06 2.73% 2,041,247 $2.20 $2.28 $2.20
    20 Jan 2025 $2.20 $-0.01 -0.45% 1,620,837 $2.21 $2.22 $2.17
    17 Jan 2025 $2.21 $0.05 2.31% 1,532,006 $2.16 $2.27 $2.15
    16 Jan 2025 $2.16 $0.06 2.86% 1,700,576 $2.18 $2.21 $2.14
    15 Jan 2025 $2.10 $-0.05 -2.33% 1,171,113 $2.11 $2.17 $2.08
    14 Jan 2025 $2.15 $0.12 5.91% 1,236,581 $2.05 $2.16 $2.03
    13 Jan 2025 $2.03 $-0.05 -2.40% 720,534 $2.04 $2.05 $2.01
    10 Jan 2025 $2.08 $0.01 0.48% 1,134,693 $2.09 $2.11 $2.05
    09 Jan 2025 $2.07 $0.01 0.49% 733,497 $2.06 $2.10 $2.05
    08 Jan 2025 $2.06 $0.01 0.49% 838,311 $2.03 $2.08 $2.01

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    10 Jan 2025 David Williams Sell 750 $1,522
    Off-market trade.
    30 Sep 2024 Andrew Lumsden Sell 50,000 $130,915
    On-market trade.
    26 Sep 2024 Leon Hoare Sell 100,000 $260,839
    On-market trade. As per announcement on 02-01-2024
    13 Sep 2024 Bruce Rathie Sell 750,000 $1,886,900
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David Williams Non-Executive DirectorNon-Executive Chairman Feb 2014
    Mr Williams is a director and investment banker with a track record in business development, mergers and acquisitions, and capital raising. He has experience advising companies in the food, medical device, and pharmaceutical sectors. Mr Williams is currently Managing Director of corporate advisory firm Kidder Williams.
    Dr Robyn Elliott Non-Executive Director Oct 2019
    Dr Elliott has a track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally. Dr Elliott was Global Head, Strategic Portfolio Management at CSL Behring, a role that is responsible for governance oversight and business value delivery. Dr Elliott is a member of the Risk Committee.
    Mr Andrew Stuart Lumsden Non-Executive Director Jun 2021
    Mr Lumsden has more than 20 years of experience locally and internationally. Mr Lumsden is currently Chief Executive Officer of Wellcom Worldwide Australasia having previously held the roles of Group Chief Financial Officer and Group Chief Operating Officer. Prior to joining Wellcom, Mr Lumsden was a Senior Manager within the Audit and Assurance practice of PricewaterhouseCoopers. Mr Lumsden is the Chair of the Risk Committee.
    Mr Leon Hoare Non-Executive Director Jan 2016
    Mr Hoare has expertise across multiple Life Sciences sectors. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew (S&N) ANZ. He served as President of S&N's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division.
    Ms Christine Emmanuel-Donnelly Non-Executive Director May 2020
    Ms Emmanuel-Donnelly is an IP and business development professional with more than 30 years of local and international experience. She has been on the Board of the Institute of Patent and Trademark Attorneys of Australia for over a decade. Ms Emmanuel-Donnelly was Executive Manager of Business Development and Commercial at the CSIRO, was in-house IP Counsel for Unilever in the U.K., and practiced as a patent and trademark attorney for Wilson Gunn.
    Mr Lior Harel Company SecretaryGeneral Counsel May 2024
    -
    Mr Swami Raote Chief Executive Officer Jul 2022
    -
    Swami Raote Chief Executive Officer
    -
    Jan Gielen Chief Financial Officer
    -
    Philip Scorgie Chief Information Officer
    -
    Joseph Amaral Chief Medical Officer (part-time)
    -
    Ingrid Anderson Chief People Officer
    -
    David McQuillan Chief Technical and Scientific Officer
    -
    Lior Harel Company SecretaryGeneral Counsel
    -
    David Morris President Asia Pacific
    -
    Edward Graubart President North America
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 96,149,727 13.93%
    J P Morgan Nominees Australia Pty Limited 80,078,534 11.60%
    Citicorp Nominees Pty Limited 37,720,578 5.46%
    Moggs Creek Pty Ltd (Moggs Creek Super A/C) 19,010,112 2.75%
    Lateral Innovations Pty Ltd (Trust A/C 10,924,103 1.58%
    Mr Anthony Shane Kittel Mrs Michele Therese Kittel (Kittel Family Super A/C) 8,050,000 1.17%
    Bnp Paribas Noms Pty Ltd 7,622,413 1.10%
    National Nominees Limited 6,653,041 0.96%
    Netwealth Investments Limited (Wrap Services A/C) 5,394,880 0.74%
    BNP Paribas Nominees Pty Ltd (IB AU Noms Retailclient) 4,533,452 0.66%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 4,414,903 0.64%
    Commonwealth Scientific And Industrial Research Organisation 4,081,250 0.59%
    Mrs Li-Hsien Tsai 3,955,424 0.57%
    Mr David Kenley 3,755,000 0.54%
    Mr Paul Gerard Brennan 3,569,796 0.52%
    Mr Matthew James Avery 3,439,332 0.50%
    Mr David Kenley i 3,139,855 0.45%
    Dr Marcus James Dermot Wagstaff Mrs Lara Kate Wagstaff 3,072,166 0.45%
    Mr Evan Philip Clucas Ms Leanne Jane Weston (Kuranga Nursery Super A/C) 2,931,149 0.42%
    Mr Chris Dawborn (Haskali Super Fund A/C) 2,870,271 0.42%

    Profile

    since

    Note